Modeling Biology, Molding Therapeutics.

Receptor Tyrosine Kinases (ROS1, ALK, ErbB3)

We define how oncogenic receptor tyrosine kinases are structured, activated, and dysregulated in cancer, leveraging structure-guided approaches to develop next-generation therapeutic antibodies and biologics.

ROS1 paper ALK paper

Metabolic Hormones (Isthmin-1 & LEG1)

We study Isthmin-1 and LEG1 as emerging metabolic regulators, uncovering their structures, receptors, and signaling mechanisms that couple nutrient status to cellular and organismal physiology.

Isthmin-1 paper

Cell Adhesion Receptors (MCAM & Nectin-2)

We define how cell adhesion receptors regulate migration, tumor–immune interactions, and metastatic progression. Through structural and mechanistic studies of MCAM and Nectin-2, we develop biologic therapeutics that modulate adhesion signaling in cancer.

Ion Channel–Mediated Signaling in Cancer

We determine how ion channel subunits (GABRP) adopt signaling functions independent of ion flux. Our work on GABA receptor architecture defines how structural rearrangements enable oncogenic signaling pathways and guide therapeutic intervention.

GABRP paper